439 related articles for article (PubMed ID: 26282624)
1. Androgen Deprivation Therapy and Secondary Hormone Therapy in the Management of Hormone-sensitive and Castration-resistant Prostate Cancer.
Saad F; Fizazi K
Urology; 2015 Nov; 86(5):852-61. PubMed ID: 26282624
[TBL] [Abstract][Full Text] [Related]
2. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
3. Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.
Damodaran S; Lang JM; Jarrard DF
J Urol; 2019 May; 201(5):876-885. PubMed ID: 30747897
[TBL] [Abstract][Full Text] [Related]
4. SRD5A gene polymorphism in Japanese men predicts prognosis of metastatic prostate cancer with androgen-deprivation therapy.
Shiota M; Fujimoto N; Yokomizo A; Takeuchi A; Itsumi M; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
Eur J Cancer; 2015 Sep; 51(14):1962-9. PubMed ID: 26169017
[TBL] [Abstract][Full Text] [Related]
5. Differential Risk of Castration Resistance After Initial Radical Prostatectomy or Radiotherapy for Prostate Cancer.
Obata H; Shiota M; Akitake N; Takeuchi A; Kashiwagi E; Dejima T; Kiyoshima K; Inokuchi J; Tatsugami K; Eto M
Anticancer Res; 2017 Oct; 37(10):5631-5637. PubMed ID: 28982880
[TBL] [Abstract][Full Text] [Related]
6. Treatment selection for men with metastatic prostate cancer who progress on upfront chemo-hormonal therapy.
Barata P; Emamekhoo H; Mendiratta P; Koshkin V; Tyler A; Ornstein M; Rini BI; Gilligan T; Kyriakopoulos C; Garcia JA
Prostate; 2018 Sep; 78(13):1035-1041. PubMed ID: 29882332
[TBL] [Abstract][Full Text] [Related]
7. Androgen deprivation of prostate cancer: Leading to a therapeutic dead end.
Katzenwadel A; Wolf P
Cancer Lett; 2015 Oct; 367(1):12-7. PubMed ID: 26185001
[TBL] [Abstract][Full Text] [Related]
8. Current state of castration-resistant prostate cancer.
Petrylak DP
Am J Manag Care; 2013 Dec; 19(18 Suppl):s358-65. PubMed ID: 24494690
[TBL] [Abstract][Full Text] [Related]
9. STAMPEDE-ing towards androgen biosynthesis inhibition for treatment of high-risk hormone-naïve prostate cancer: changing the LATITUDE.
Klaassen Z; Murphy DG
BJU Int; 2018 Jan; 121(1):9-11. PubMed ID: 28990349
[No Abstract] [Full Text] [Related]
10. [New therapies in metastatic castration resistant prostate cancer].
Thibault C; Massard C
Bull Cancer; 2015 Jun; 102(6):501-8. PubMed ID: 26022286
[TBL] [Abstract][Full Text] [Related]
11. Therapies for castration-resistant prostate cancer in a new era: The indication of vintage hormonal therapy, chemotherapy and the new medicines.
Mizokami A; Kadono Y; Kitagawa Y; Izumi K; Konaka H
Int J Urol; 2017 Aug; 24(8):566-572. PubMed ID: 28577511
[TBL] [Abstract][Full Text] [Related]
12. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
[TBL] [Abstract][Full Text] [Related]
13. Enzalutamide for the treatment of metastatic castration-resistant prostate cancer.
Rodriguez-Vida A; Galazi M; Rudman S; Chowdhury S; Sternberg CN
Drug Des Devel Ther; 2015; 9():3325-39. PubMed ID: 26170619
[TBL] [Abstract][Full Text] [Related]
14. [Qualitative and quantitative hormonal regulation in castration-resistant prostate cancer].
Murez T; Basset V; Audenet F; Lebret T; Branchereau J
Prog Urol; 2013 Oct; 23 Suppl 1():S1-8. PubMed ID: 24314734
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
16. Simple risk assessment in prostate cancer patients treated with primary androgen deprivation therapy: The Korean Cancer Study of the Prostate risk classification.
Choi SY; Ryu J; You D; Hong JH; Ahn H; Kim CS
Int J Urol; 2019 Jan; 26(1):62-68. PubMed ID: 30238513
[TBL] [Abstract][Full Text] [Related]
17. Recent trends in the management of advanced prostate cancer.
Ritch C; Cookson M
F1000Res; 2018; 7():. PubMed ID: 30345007
[TBL] [Abstract][Full Text] [Related]
18. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
Fizazi K; Faivre L; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houede N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Chinet-Charrot P; Legouffe E; Lagrange JL; Linassier C; Deplanque G; Beuzeboc P; Davin JL; Martin AL; Habibian M; Laplanche A; Culine S
Lancet Oncol; 2015 Jul; 16(7):787-94. PubMed ID: 26028518
[TBL] [Abstract][Full Text] [Related]
19. GPX2 overexpression is involved in cell proliferation and prognosis of castration-resistant prostate cancer.
Naiki T; Naiki-Ito A; Asamoto M; Kawai N; Tozawa K; Etani T; Sato S; Suzuki S; Shirai T; Kohri K; Takahashi S
Carcinogenesis; 2014 Sep; 35(9):1962-7. PubMed ID: 24562575
[TBL] [Abstract][Full Text] [Related]
20. The effect of continuous androgen deprivation treatment on prostate cancer patients as compared with intermittent androgen deprivation treatment.
Ku JY; Lee JZ; Ha HK
Korean J Urol; 2015 Oct; 56(10):689-94. PubMed ID: 26495069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
